Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies

Timothy Hughes, Michael Mauro, Susan Branford, Wei Deng, Qi Wang, Helen Collins, Andreas Hochhaus

Blood (2022) 140 (Supplement 1): 6780–6781.

https://doi.org/10.1182/blood-2022-170401

Published: 2022

Journal Articles

Novel Antibodies Against Glycoprotein Ibα Inhibit Pulmonary Metastasis By Affecting Vwf-Gpibα Interaction

Qi Yingxue, Wenchun Chen, PhD, Ke Xu, Fengying Wu, Xuemei Fan, Shengxiang Ren, Junling Liu, Wei Deng, PhD, Jun Zhang, Renhao Li, PhD, Jianwen Liu, Xin Liang, PhD

Blood (2018) 132 (Supplement 1): 1133.

https://doi.org/10.1182/blood-2018-99-117613

Published: 2018

Journal Articles

Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets

M. Edward Quach, Matthew A. Dragovich, Wenchun Chen, Anum K. Syed, Wenpeng Cao, Xin Liang, Wei Deng, Simon F. De Meyer, Guangheng Zhu, Jun Peng, Heyu Ni, Carolyn M. Bennett, Ming Hou, Jerry Ware, Hans Deckmyn, X. Frank Zhang, Renhao Li

Blood (2018) 131 (7): 787–796.

https://doi.org/10.1182/blood-2017-05-784975

Published: 2018

Includes: Supplemental data

Journal Articles

Mapping the Masked Region of the A1 Domain in Full-Length VWF

Wei Deng, PhD, Ernest T. Parker, BA, John S. Lollar, MD, Renhao Li, PhD

Blood (2017) 130 (Supplement 1): 3599.

https://doi.org/10.1182/blood.V130.Suppl_1.3599.3599

Published: 2017

Journal Articles

Calcium-Induced Conformational Changes in EF hands and Autoinhibitory Linker Region are Critical for Catalytic Activity of CalDAG-GEFI Towards the Small GTPase Rap1

Aaron Cook, Wei Deng, PhD, Renhao Li, PhD, John Sondek, PhD, Wolfgang Bergmeier, PhD

Blood (2017) 130 (Supplement 1): 3614.

https://doi.org/10.1182/blood.V130.Suppl_1.3614.3614

Published: 2017

Journal Articles

Structural Basis for the Procofactor to Cofactor Transition in Human Factor V

Shekhar Kumar, PhD, Wei Deng, PhD, Steven Stayrook, PhD, Renhao Li, PhD, Rodney M. Camire, PhD, Sriram Krishnaswamy, PhD

Blood (2016) 128 (22): 253.

https://doi.org/10.1182/blood.V128.22.253.253

Published: 2016

Journal Articles

HMPL-523, a Novel SYK Inhibitor Showed Anti-Tumor Activities In Vitro and In Vivo

Na Yang, Wei Deng, Qiaoling Sun, Junqing Liang, Linfang Wang, Shiming Fan, Renxiang Tang, Ying Yu, Junen Sun, Feng Zhou, Guangxiu Dai, Weiguo Qing, Weiguo Su, Yongxin Ren

Blood (2016) 128 (22): 3970.

https://doi.org/10.1182/blood.V128.22.3970.3970

Published: 2016

Journal Articles

A Short N-Terminal Fragment in Front of the A1 Domain of Von Willebrand Factor Prevents the A1 from Binding the Platelet By Masking a Region Clustered By Type 2B VWD Mutations

Wei Deng, PhD, Yingchun Wang, PhD, Pete Lollar, MD, Renhao Li, PhD

Blood (2016) 128 (22): 553.

https://doi.org/10.1182/blood.V128.22.553.553

Published: 2016

Journal Articles

High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors

Glaivy Batsuli, Wei Deng, John F. Healey, Ernest T. Parker, W. Hunter Baldwin, Courtney Cox, Brenda Nguyen, Joerg Kahle, Christoph Königs, Renhao Li, Pete Lollar, Shannon L. Meeks

Blood (2016) 128 (16): 2055–2067.

https://doi.org/10.1182/blood-2016-02-701805

Published: 2016

Includes: Supplemental data

Journal Articles

Identification of a juxtamembrane mechanosensitive domain in the platelet mechanosensor glycoprotein Ib-IX complex

Wei Zhang, Wei Deng, Liang Zhou, Yan Xu, Wenjun Yang, Xin Liang, Yizhen Wang, John D. Kulman, X. Frank Zhang, Renhao Li

Blood (2015) 125 (3): 562–569.

https://doi.org/10.1182/blood-2014-07-589507

Published: 2015

Includes: Supplemental data

Journal Articles

The Relative Bioavailability, Food Effect and Drug Interaction With Omeprazole Of Momelotinib Tablet Formulation

Yan Xin, PhD, Lixin Shao, MD MS, Wei Deng, PhD, Amanda Shaffer, Pharm D, Dimitrios Stefanidis, PhD, Jeffrey Hemenway, PhD, Xiaoming Li, PhD, Susie Jun, MD, PhD, Srini Ramanathan, PhD

Blood (2013) 122 (21): 5239.

https://doi.org/10.1182/blood.V122.21.5239.5239

Published: 2013

Journal Articles

Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis

Yan Xin, PhD, Lixin Shao, MD MS, Wei Deng, PhD, Demi Niforos, MS, Mark Kowalski, MD, PhD, Linda M Bavisotto, MD, Jun Kawashima, MD, Susie Jun, MD, PhD, Helen Collins, MD, Srinivasan Ramanathan, PhD

Blood (2013) 122 (21): 1590.

https://doi.org/10.1182/blood.V122.21.1590.1590

Published: 2013

Journal Articles

Cooperative Binding Of Anti-Factor VIII Inhibitors and Induced Conformational Change Detected By Hydrogen-Deuterium Exchange Mass Spectrometry

Shannon L. Meeks, MD, Alexander M. Sevy, B.S., John F. Healey, B.S., Wei Deng, Ph.D., P. Clint Spiegel, Ph.D., Renhao Li, PhD

Blood (2013) 122 (21): 1088.

https://doi.org/10.1182/blood.V122.21.1088.1088

Published: 2013

Journal Articles

Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis

Animesh Pardanani, MBBS, PhD, Jason Gotlib, MD, MS, Vikas Gupta, MD, FRCP, FRCPath, Andrew W. Roberts, MBBS, PhD, Martha Wadleigh, MD, Shireen Sirhan, MD, FRCP, Linda M Bavisotto, MD, Jun Kawashima, MD, Peter Lee, MD, PhD, Mark Kowalski, MD, PhD, Wei Deng, PhD, Demi Niforos, MS, Ayalew Tefferi, MD

Blood (2013) 122 (21): 108.

https://doi.org/10.1182/blood.V122.21.108.108

Published: 2013

Journal Articles

A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results

Paul G. Richardson, MD, Sundar Jagannath, MD, Philippe Moreau, MD, Andrzej Jakubowiak, MD, PhD, Marc S Raab, Thierry Facon, MD, Ravi Vij, MBBS, Darrell J. White, MD, Donna Reece, Lotfi Benboubker, MD, PhD, Jeffrey A. Zonder, MD, Wei Deng, Glenn Kroog, MD, Anil K Singhal, MD, Sagar Lonial, MD

Blood (2012) 120 (21): 202.

https://doi.org/10.1182/blood.V120.21.202.202

Published: 2012

Journal Articles

Long-Term Safety and Efficacy of Deferasirox (Exjade ® ) In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years

Elliott Vichinsky, MD, Francoise Bernaudin, MD, Gian Luca Forni, MD, Renee Gardner, MD, Kathryn Hassell, MD, Matthew M. Heeney, MD, Baba Inusa, MD, Abdullah Kutlar, MD, Peter A. Lane, MD, Liesl Mathias, MD, John B. Porter, MD, Cameron K Tebbi, MD, Felicia L. Wilson, MD, Louis Griffel, MD, Wei Deng, PhD, Vanessa Giannone, BSN, Thomas D. Coates, MD

Blood (2010) 116 (21): 845.

https://doi.org/10.1182/blood.V116.21.845.845

Published: 2010

NARROW

First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies

Novel Antibodies Against Glycoprotein Ibα Inhibit Pulmonary Metastasis By Affecting Vwf-Gpibα Interaction

Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets

Mapping the Masked Region of the A1 Domain in Full-Length VWF

Calcium-Induced Conformational Changes in EF hands and Autoinhibitory Linker Region are Critical for Catalytic Activity of CalDAG-GEFI Towards the Small GTPase Rap1

Structural Basis for the Procofactor to Cofactor Transition in Human Factor V

HMPL-523, a Novel SYK Inhibitor Showed Anti-Tumor Activities In Vitro and In Vivo

A Short N-Terminal Fragment in Front of the A1 Domain of Von Willebrand Factor Prevents the A1 from Binding the Platelet By Masking a Region Clustered By Type 2B VWD Mutations

High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors

Identification of a juxtamembrane mechanosensitive domain in the platelet mechanosensor glycoprotein Ib-IX complex

The Relative Bioavailability, Food Effect and Drug Interaction With Omeprazole Of Momelotinib Tablet Formulation

Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis

Cooperative Binding Of Anti-Factor VIII Inhibitors and Induced Conformational Change Detected By Hydrogen-Deuterium Exchange Mass Spectrometry

Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis

A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results

Long-Term Safety and Efficacy of Deferasirox (Exjade ® ) In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only